The webinar discusses innovative platforms shaping next-generation antibody-drug conjugates (ADCs) to address resistance and off-target toxicity. Experts from ChemPartner present on multi-targeting precision through novel antibody formats, new linker technology for enhanced stability in vivo, and dual-payload ADCs to target multiple cellular pathways simultaneously. The session includes live Q&A with the panelists.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



